Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
RegulatoryWatchMinormateriality 56 out of 100
What happened
FactPendency of Litigation(s)/dispute(s) or the outcome impacting the Company. AdvaGen Pharma Ltd, USA, a material step down subsidiary company, is in receipt of demand notice under. (Formerly known as Rubicon Research Private Limited).
Why it matters
CapitSignal interpretationLitigation creates a contingent liability that is not in reported profit until it crystallises.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
ContradictedEarlierQ1 FY27
This operational facility manufactures oral solid and oral liquid formulations and has been USFDA inspected for over a decade with 3 successful inspections.
NowQ1 FY27
We expect to commence manufacturing our products at the site in calendar year 2027 after completing implementation of our quality management systems.
Change
FactFact conflict
Implication
CapitSignal interpretationThe earlier statement claims that the facility has been operational and has been manufacturing for over a decade, while the current statement indicates that manufacturing is expected to commence in calendar year 2027, suggesting it is not currently operational.
Watch next
Fact- Amount claimed against the company
- Whether a provision has been made
- Next hearing or order date
- We expect to commence manufacturing our products at the site in calendar year 2027 after completing implementa (management committed by FY27)
- So, on the Capex guidance, Ritika, I put it in two parts. One is that for the next couple of year, we are proj (management committed by FY27)
Evidence
- Rubicon Research Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q2 FY25
How CapitSignal classified this
- Reasoning:
- LITIGATION base 56; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%